Sunshine Biopharma EPS SBFM
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2025
- −$702.00
- Latest quarter, Q2 FY25
- −$164.00
- Fiscal year 2024
- −$17146.00
Sunshine Biopharma's earnings per share was −$702.00 over the twelve months to Jun 30, 2025.
In its latest quarter, Q2 FY25, it was −$164.00.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$17146.00 | n/a |
| FY2023 | −$61078.00 | n/a |
| FY2022 | −$560000.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY25 | −$164.00 | n/a | −$702.00 | |
| Q1 FY25 | −$88.00 | n/a | −$9234.00 | |
| Q4 FY24 | −$262.00 | n/a | −$17146.00 | |
| Q3 FY24 | −$188.00 | n/a | −$36884.00 | |
| Q2 FY24 | −$8696.00 | n/a | −$46840.00 | |
| Q1 FY24 | −$8000.00 | n/a | −$38158.00 | |
| Q4 FY23 | −$20000.00 | n/a | −$61078.00 | |
| Q3 FY23 | −$10144.00 | n/a | −$465078.00 | |
| Q2 FY23 | −$14.00 | n/a | −$486934.00 | |
| Q1 FY23 | −$30920.00 | n/a | −$498920.00 | |
| Q4 FY22 | −$424000.00 | n/a | −$560000.00 | |
| Q3 FY22 | −$32000.00 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Sunshine Biopharma's size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| SBFMSunshine Biopharma | n/m |
| VBIOValion Bio | n/m |
| LABTLakewood-Amedex Biotherapeutics | n/m |
| DCOYDecoy Therapeutics | n/m |
| NXTSNexentis Technologies | n/m |
| LNAILunai Bioworks | n/m |
| JAGXJaguar Health | −$6051.75 |
| ARTLArtelo Biosciences | −$207.09 |
| GOVXGeoVax Labs | n/m |
| MTNBMatinas BioPharma | −$18.15 |
| KAPAKairos Pharma, LTD. | −$1.96 |
| Peer median | −$112.62 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Sunshine Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.